Medical oncology: Treatment and management of malignant gliomas

Nature Reviews Clinical Oncology

Volumn 7, Issue 2, 2010, Pages 75-77

  Park, Deric M ^a   Sathornsumetee, Sith ^b   Rich, Jeremy N ^c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CEDIRANIB; IRINOTECAN; ISOCITRATE DEHYDROGENASE; LOMUSTINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TEMOZOLOMIDE; TIRAPAZAMINE;

CANCER GENETICS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURGERY; CLINICAL TRIAL; GENE MUTATION; GLIOBLASTOMA; HUMAN; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RECURRENT CANCER; SHORT SURVEY; TREATMENT FAILURE; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; GLIOBLASTOMA; HUMANS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 76449102436     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.221     Document Type: Short Survey

References (10)

1. stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
2. vredenburgh, J. J. et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25, 4722-4729 (2007).
3. Friedman, H. s. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733-4740 (2009).
4. Batchelor, T. T. et al. AZD2171, a pan-veGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
5. Pàez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).
6. The Cancer Genome Atlas Research network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
7. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
8. Bao, s. et al. Glioma stem cells promote radioresistance by preferential activation of the DnA damage response. Nature 444, 756-760 (2006).
9. Li, Z. et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15, 501-513 (2009).
10. sathornsumetee, s. et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol. 26, 271-278 (2008).